Two B7-H3 antibody drug conjugates cut death risk 54% in relapsed SCLC, Gilead and Merck's trial only worked in Chinese patients, and Novartis loses its radioligand monopoly (Sep 11–17, 2026).
The confirmation took an extra 14 months of follow up. No deal process tolerates 14 months, so the asset changes hands on the signal and the acquirer books the geography question as a discount rather than a doubt. That is not a lapse in rigor. It is the pricing. Whoever waits for the confirmed version pays for a confirmed version, and by then it belongs to someone else.
Glad to have found this, looking forward to adding this to my weekly listening/reading routine.
Thank you, James! Hope you enjoy reading Biotech Blueprint:)
The confirmation took an extra 14 months of follow up. No deal process tolerates 14 months, so the asset changes hands on the signal and the acquirer books the geography question as a discount rather than a doubt. That is not a lapse in rigor. It is the pricing. Whoever waits for the confirmed version pays for a confirmed version, and by then it belongs to someone else.